会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Methods of modulating matrix metalloproteinase activity and uses thereof
    • 调节基质金属蛋白酶活性的方法及其应用
    • US06403637B1
    • 2002-06-11
    • US09370738
    • 1999-08-09
    • Nicola C. Partridge
    • Nicola C. Partridge
    • A61K3135
    • C12Q1/37A61K31/00A61K31/22A61K31/366A61K31/40G01N2500/10
    • Methods for inactivating matrix metalloproteinases in a vertebrate cell are disclosed. The methods comprise administering to the cell an agent which causes increased endocytosis of the matrix metalloproteinase. Methods for treating vertebrates with disorders mediated by matrix metalloproteinases are also disclosed. These methods comprise administering the above-described agents to the vertebrate. Also disclosed is the use of HMG-CoA reductase inhibitors, also known as statins, as an agent which causes increased endocytosis of matrix metalloproteinases. Assays for determining whether an agent is effective in treating a disorder are also disclosed. These assays comprise testing the agent for activity in increasing endocytosis of a matrix metalloproteinase which mediates the disorder.
    • 公开了在脊椎动物细胞中灭活基质金属蛋白酶的方法。 所述方法包括向细胞施用引起基质金属蛋白酶内吞作用的试剂。 还公开了用基质金属蛋白酶介导的疾病治疗脊椎动物的方法。 这些方法包括将上述试剂施用于脊椎动物。 还公开了HMG-CoA还原酶抑制剂(也称为他汀类)作为引起基质金属蛋白酶内吞的药物的用途。 还公开了用于确定试剂是否有效治疗病症的测定。 这些测定法包括测试该药物的活性,以增加介导病症的基质金属蛋白酶的内吞作用。